Top Markets
#1 MarsCoin MarsCoin +46.67%
#2 Palladium Network Palladium Network +27.97%
#3 Siren Siren +27.76%
#4 Status Status +19.63%
#5 Useless Coin Useless Coin +18.72%
#6 Bedrock Bedrock +15.94%
#7 BankrCoin BankrCoin +15.33%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.19%
#9 Ankr Network Ankr Network +13.10%
#10 Arweave Arweave +10.04%
Coin of the day
MarsCoin MarsCoin
Settings
Language
ENGLISH
Currency
USD
Theme
KemPharm, Inc. KemPharm, Inc.

KemPharm, Inc.

KMPH
Rank in Stocks #18404
KemPharm, Inc. operates as a specialized pharmaceutical firm focused on... KemPharm, Inc. operates as a specialized pharmaceutical firm focused on discovering and advancing proprietary prodrugs to tackle serious medical conditions across the United States. The company employs its innovative Ligand Activated Therapy (LAT) platform to create improved prodrug versions of medications already approved by the FDA, and also to develop prodrugs from existing compounds for potential applications in new disease indications. Its pipeline of investigational prodrugs strategically targets high-need areas such as attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) disorders, including idiopathic hypersomnia (IH). KP1077, KemPharm's leading experimental compound, is a prodrug of d-methylphenidate, known as serdexmethylphnidate, and is currently in Phase II clinical trials for the treatment of IH and narcolepsy. Additionally, the company is advancing KP879, a prodrug candidate designed to treat stimulant use disorder, which is undergoing Phase I clinical evaluation. KemPharm has also obtained FDA approval for AZSTARYS, a new once-daily ADHD treatment for patients aged six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company holds collaboration and license agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Founded in 2006, KemPharm, Inc. is headquartered in Celebration, Florida.
Share Price
$5.81
Last synced: 2023-02-28
Market Cap
$200.14M
Change (1 day)
-0.34%
Change (1 year)
0.00%
Country
US
Trade KemPharm, Inc. (KMPH)

Category

Healthcare
Stock price history for KemPharm, Inc. (KMPH)
Highest end of day price: $5.54 on 2023-02-01

Lowest end of day price: $11.07 on 2015-04-01
Stock price history of KemPharm, Inc. from 2015 to 2026
Annual Stock Price Performance
Year Performance
2023 22.80%
2022 -46.25%
2021 3,183.01%
2020 -31.88%
2019 -83.62%
2018 -39.43%
2017 8.52%
2016 -80.65%
2015 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $556.43 40.29%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.05K 45.39%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $152.82 535.43%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $123.39 -8.70%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $757.71 6.76%
CH